No neurochemical evidence for brain injury caused by heading in soccer

Henrik Zetterberg, Michael Jonsson, Abdullah Rasulzada, Cornel Popa, Ewa Styrd, Max Albert Hietala, Lars Rosengren, Anders Wallin, Kaj Blennow

Br J Sports Med 2007;41:574–577. doi: 10.1136/bjsm.2007.037143

See end of article for authors' affiliations

Correspondence to:
Dr H Zetterberg, Department
of Neurochemistry,
Sahlgrenska University
Hospital/Mölndal, S-431 80
Mölndal, Sweden; henrik.
zetterberg@clinchem.gu.se

Accepted 27 March 2007
Published Online First
11 May 2007

Background: The possible injurious effect to the brain of heading in soccer is a matter of discussion.

Objective: To determine whether standardised headings in soccer are associated with increased levels of biochemical markers for neuronal injury in cerebrospinal fluid (CSF) and serum.

Methods: 23 male amateur soccer players took part in a heading training session involving heading a ball kicked from a distance of 30 m at least 10 m forward. Ten players performed 10 and 13 players performed 20 approved headings. The players underwent lumbar puncture and serum sampling 7–10 days after the headings. The study also included 10 healthy male non-athletic control subjects. CSF was analysed for neurofilament light protein, total tau, glial fibrillary acidic protein, S-100B and albumin concentrations. Serum was analysed for S-100B and albumin.

Results: None of the biomarker levels were abnormal and there were no significant differences between any of the three groups, except for a slightly increased CSF S-100B concentration in controls compared with headers. Biomarker levels did not correlate with the number of headings performed.

Conclusion: Repeated low-severity head impacts due to heading in soccer are not associated with any neurochemical signs of injury to the brain.

There has been growing controversy about the possible injurious effects to the brain of repeated low-severity head impacts, such as when heading a football.¹ However, there are few scientific data substantiating these concerns with direct evidence for neuronal damage in response to the impact. In a series of retrospective studies including retired Norwegian soccer players, cognitive deficits were noted.^{2–3} Similar results have been obtained in some American studies.⁴ In contrast, other studies have failed to show any signs of brain damage in soccer players.^{5–6} The conflicting data may be explained by methodological problems that may affect some of these studies, including the lack of pre-injury data, selection bias, failure to control for acute head injuries, lack of blinding of observers, and inadequate controls.

Two recent observational studies that determined serum concentrations of two biochemical markers for brain damage, S-100B and neurone specific enolase, in elite soccer players before and after a competitive game showed that both markers were increased by game-related activities and that the S-100B levels correlated with the number of headings.^{7–8} However, S-100B may also be released from extracerebral tissue in response to trauma not involving the brain,^{9–10} which makes the data somewhat uncertain.

The best-established biomarkers for neuronal injury are those analysed in cerebrospinal fluid (CSF), which is in direct contact with the brain interstitial fluid without any barriers. Hence, changes in neuronal function, metabolism and survival and host responses to neuronal injury are more likely to be directly reflected in the CSF proteome than in peripheral blood. CSF biomarkers of brain injury include total tau (T-tau) and neurofilament light (NF-L) proteins that reflect axonal injury,^{11–12} and the intermediate filament protein glial fibrillary acidic protein (GFAP) and the calcium-binding protein S-100B that reflect injury to glial cells.^{13–14} For example, in stroke there is a marked, transient increase in the CSF levels of these proteins that correlates with the infarct size.^{15–17} Also, very minor strokes can be detected.¹⁷ In amateur boxing, we recently

found evidence for subclinical injury to brain tissue using these markers.¹⁸ The increase was most pronounced for NF-L and correlated with the number of head punches received, although no boxer had been knocked out. Another possible challenge to the brain, electroconvulsive treatment, does not result in any change in CSF biomarker levels,^{19–20} and there is now a consensus that this procedure is harmless to the central nervous system.²¹ Hence, CSF T-tau, NF-L, GFAP and S-100B are sensitive and specific indicators of damage to the brain. Here, we examined the possible brain-damaging effects of heading in soccer by conducting an experimental study on CSF biomarker levels in amateur players who performed standardised headings as a part of a training session.

SUBJECTS AND METHODS

Subjects and experimental setting

Twenty-three male amateur soccer players participated in a training session that involved heading a ball kicked from a distance of 30 m in front of the player. The players were required to head the ball from a standing position at least 10 m forward with an allowed deviation of 45° to each side (fig 1). The 30 m distance translates well to a regular corner kick. Ten players performed 10 and 13 players performed 20 approved headings. The total number of headings (approved and unapproved) ranged from 11 to 57. The ball used was an Adidas Teamgeist 2006 FIFA World Cup Official Match soccer ball fulfilling the FIFA approved standard of a weight between 420 and 445 g and a circumference of 68.5–69.5 cm. The ball was inflated to a pressure of 900 g/cm² (FIFA approved standard 600–1100 g/cm²).

Seven to 10 days after the training session the participants underwent lumbar puncture (LP) through the L3/L4 interspace for collection of CSF, and venous puncture for collection of

Abbreviations: CSF, cerebrospinal fluid; GFAP, glial fibrillary acidic protein; LP, lumbar puncture; NF-L, neurofilament light protein; T-tau, total tau

Figure 1 Schematic illustration of the experimental setting. One player kicks the ball at a distance of 30 m to the header, who heads the ball from a standing position at least 10 m forward. A deviation of 45° to each side is allowed. The header is allowed to run to a standing position within a 5 m square to position himself for the heading. The hatched lines demark the area in which the ball should land if a heading is to be approved.

serum. The 7–10-day time point was chosen as the optimal point at which to detect a change in biomarker levels as a result of the headings on the basis of CSF biomarker kinetics in a study on stroke.¹⁶ CSF was collected in polypropylene tubes, aliquoted and stored at –80°C pending analysis. The participants were examined physically and neurologically before the LP. All were healthy and none showed any signs of focal neurological injury. The study also included 10 healthy, male, age-matched, non-athletic control subjects who underwent LP and serum sampling but who did not participate in any activities involving head impacts. One control was excluded owing to marked blood contamination of the CSF. The study was approved by the ethics committee of Göteborg University, and written informed consent was obtained from all participants.

Biochemical analyses

CSF T-tau concentration was determined by a sandwich ELISA (Innotest hTAU-Ag, Innogenetics, Gent, Belgium) specifically

constructed to measure all tau isoforms irrespectively of phosphorylation status, as previously described.²² CSF concentrations of NF-L and GFAP were analysed using previously described ELISA methods.^{14–17} The detection limit of the NF-L ELISA was 125 ng/l. Serum and CSF levels of S-100B were determined by an electrochemoluminescence immunoassay using the Modular system and the S100 reagent kit (Roche Diagnostics). Albumin levels in CSF and serum were measured by immunonephelometry on a Beckman Image Immunochemistry system (Beckman Instruments, Fullerton, California, USA). The albumin ratio was calculated as CSF albumin (mg/l)/serum albumin (g/l). The coefficients of variation for all biochemical analyses were <10%.

Statistics

The statistical calculations were performed using SYSTAT 11.0 (SYSTAT Software GmbH, Erkrath, Germany). The non-parametric Kruskal–Wallis test was used for comparisons between groups for quantitative variables. The Pearson correlation coefficient was used for analyses of correlation between biomarker levels and number of headings. A value of $p < 0.05$ was considered significant.

RESULTS

No significant differences were found between CSF or serum biomarker concentrations between soccer players who had performed 10 or 20 approved headings (table 1). Likewise, there were no significant differences between either of these two groups and the control group, except for a slightly increased CSF S-100B concentration in the control group compared with players with 10 and 20 approved headings ($p = 0.049$ and $p = 0.008$, respectively, table 1). There were no correlations between the number of approved headings or the total number of headings and any of the biomarker levels (table 2), and there were no intraindividual correlations between any of the biomarkers in any of the groups or in the whole material (data not shown).

DISCUSSION

The current study is to our knowledge the first determined attempt to determine whether there is a direct injurious effect of heading on brain tissue as reflected by CSF levels of T-tau, NF-L, GFAP and S-100B, which are sensitive and specific markers for neuronal and astroglial injury.²³ Further, we assessed brain-barrier function using the albumin ratio, and serum levels of S-100B, which may reflect injury to the brain. In contrast to our earlier finding for amateur boxing, where increased levels of T-tau, NF-L and GFAP that correlated with the number of received head punches were detected,¹⁸

Table 1 Demographic and biochemical variables in soccer players and controls*

Variables	Soccer players with 10 approved headings (n = 10)	Soccer players with 20 approved headings (n = 13)	Controls (n = 9†)
Age (years)	26 (19–32)	23 (20–28)	24 (22–27)
Total number of headings	14 (11–20)	23 (20–57)	0
Albumin ratio	4.1 (2.4–9.3)	3.9 (2.0–8.7)	4.1 (2.5–6.3)
NF-L (ng/l)	<125	<125	<125
T-tau (ng/l)	315 (170–400)	250 (190–420)	320 (120–540)
GFAP (ng/l)	265 (180–510)	260 (190–330)	280 (190–460)
S-100B in CSF (µg/l)	0.87 (0.71–1.2)	0.82 (0.48–1.3)	1.1 (0.77–1.2)‡
S-100B in serum (µg/l)	0.060 (0.030–0.12)	0.040 (0.010–0.07)	0.040 (0.030–0.060)

*Data are presented as median (range).
†One of the 10 controls was excluded because of bleeding caused by the lumbar puncture.
‡ $p = 0.049$ for controls vs players with 10 approved headings and $p = 0.008$ for controls vs players with 20 approved headings.

Table 2 Correlations between total number of headings and biomarker levels in the whole group of soccer players (n = 23)*

Variables	Sample correlation coefficient	95% CI	p Value
Albumin ratio	0.37	−0.047 to 0.68	0.080
T-tau	−0.004	−0.42 to 0.41	0.98
GFAP	−0.19	−0.56 to 0.24	0.38
S-100B in CSF	−0.019	−0.43 to 0.40	0.93
S-100B in serum	−0.35	−0.67 to 0.069	0.099

CSF, cerebrospinal fluid; GFAP, glial fibrillary acidic protein; T-tau, total tau.

*No correlation for neurofilament light protein (NF-L) is presented since the NF-L concentration was <125 ng/l in all samples.

the results of this study suggest that standardised headings in soccer do not result in neuronal or astroglial injury. Notably, the CSF levels of these biomarkers are more likely to reflect damage to brain tissue in a sensitive and specific manner than the corresponding serum levels, which may be influenced by biomarker release from extracerebral tissues.^{9, 10}

The reason for the slightly increased S-100B levels in CSF from controls compared with soccer players is unknown, but it should be noted that they are well below the levels found in independent control populations that were used when establishing clinical reference values for this analyte in our laboratory (CSF S-100B <1.7 µg/l).

It is estimated that professional soccer players head the ball five to six times a game.²⁴ Thus, the negative results in this study are unlikely to be because the number of headings performed by the participants was too low. Further, the distance of the ball flight of 30 m is similar to a regular corner kick, which is a common reason for heading in soccer. Finally, numerous studies from our laboratory and others show that the CSF biomarkers employed in this study are sensitive and specific markers for damage to the brain, including diffuse axonal injury and subclinical neuronal and astroglial injury in boxers.^{16–18, 23, 25–27}

In conclusion, this study suggests that the head-to-ball contact in a controlled heading does not cause any acute neuronal or astroglial injury. In agreement with this view, the majority of head injuries in soccer seem to be caused by

head-to-head contact with another player or goalpost collisions.²⁸ Thus, efforts to prevent brain injury associated with heading may be focused on reducing the likelihood of head-to-head or head-to-goalpost contact and improving the technique so that uncontrolled head-to-ball contact is avoided.

ACKNOWLEDGEMENTS

This work was supported by grants from the Swedish Research Council, the Swedish Council for Working Life and Social Research, and the Göteborg Medical Society. We thank all participants, and Anne Nyman, Monica Christiansson, Åsa Källén, Shirley Fridlund and Mona Thunell for excellent technical assistance. Funding sources played no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review or approval of the manuscript.

Authors' affiliations

Henrik Zetterberg, Michael Jonsson, Abdullah Rasulzada, Cornel Popa, Ewa Styrd, Anders Wallin, Kaj Blennow, Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, the Sahlgrenska Academy at Göteborg University, Göteborg, Sweden
Max Albert Hietala, Lars Rosengren, Institute of Neuroscience and Physiology, Department of Neurology, the Sahlgrenska Academy at Göteborg University, Göteborg, Sweden

Competing interests: None.

REFERENCES

- 1 McCrory PR. Brain injury and heading in soccer. *BMJ* 2003;**327**:351–2.
- 2 Tysvaer AT. Head and neck injuries in soccer. Impact of minor trauma. *Sports Med* 1992;**14**:200–13.
- 3 Tysvaer AT, Storli OV, Bachen NI. Soccer injuries to the brain. A neurologic and electroencephalographic study of former players. *Acta Neurol Scand* 1989;**80**:151–6.
- 4 Rutherford A, Stephens R, Potter D. The neuropsychology of heading and head trauma in Association Football (soccer): a review. *Neuropsychol Rev* 2003;**13**:153–79.
- 5 Guskiewicz KM, Marshall SW, Broglio SP, et al. No evidence of impaired neurocognitive performance in collegiate soccer players. *Am J Sports Med* 2002;**30**:157–62.
- 6 Straume-Naesheim TM, Andersen TE, Dvorak J, et al. Effects of heading exposure and previous concussions on neuropsychological performance among Norwegian elite footballers. *Br J Sports Med* 2005;**39**(Suppl 1):i70–7.
- 7 Stalnacke BM, Ohlsson A, Tegner Y, et al. Serum concentrations of two biochemical markers of brain tissue damage S-100B and neuron specific enolase are increased in elite female soccer players after a competitive game. *Br J Sports Med* 2006;**40**:313–6.
- 8 Stalnacke BM, Tegner Y, Sojka P. Playing soccer increases serum concentrations of the biochemical markers of brain damage S-100B and neuron-specific enolase in elite players: a pilot study. *Brain Inj* 2004;**18**:899–909.
- 9 Korfiatis S, Stranjalis G, Psachoulia C, et al. Slight and short-lasting increase of serum S-100B protein in extra-cranial trauma. *Brain Inj* 2006;**20**:867–72.
- 10 Unden J, Bellner J, Eneroth M, et al. Raised serum S100B levels after acute bone fractures without cerebral injury. *J Trauma* 2005;**58**:59–61.
- 11 Friede RL, Samorajski T. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. *Anat Rec* 1970;**167**:379–87.
- 12 Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. *Trends Neurosci* 1993;**16**:460–5.
- 13 Fano G, Biocca S, Fulle S, et al. The S-100: a protein family in search of a function. *Prog Neurobiol* 1995;**46**:71–82.
- 14 Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. *J Neurosci Methods* 1994;**51**:197–204.
- 15 Hesse C, Rosengren L, Vanmechelen E, et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. *J Alzheimers Dis* 2000;**2**:199–206.
- 16 Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. *Neurosci Lett* 2001;**297**:187–90.
- 17 Rosengren LE, Karlsson JE, Karlsson JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. *J Neurochem* 1996;**67**:2013–8.
- 18 Zetterberg H, Hietala MA, Jonsson M, et al. Neurochemical aftermath of amateur boxing. *Arch Neurol* 2006;**63**:1277–80.
- 19 Agelink MW, Andrich J, Postert T, et al. Relation between electroconvulsive therapy, cognitive side effects, neuron specific enolase, and protein S-100. *J Neurol Neurosurg Psychiatry* 2001;**71**:394–6.

What is already known on this topic

- CSF biomarkers can detect acute subclinical brain injury caused by amateur boxing.
- There are limited data available on the possible injurious effects to the brain of repeated headings in soccer.

What this study adds

- Standardised headings in soccer are not associated with any biochemical signs of neuronal or astroglial injury.
- The biomechanical effect on the brain of heading in soccer seems quite different from that caused by head punches in boxing.

- 20 Zachrisson OC, Balldin J, Ekman R, *et al.* No evident neuronal damage after electroconvulsive therapy. *Psychiatry Res* 2000;**96**:157–65.
- 21 Greenberg RM, Kellner CH. Electroconvulsive therapy: a selected review. *Am J Geriatr Psychiatry* 2005;**13**:268–81.
- 22 Blennow K, Wallin A, Agren H, *et al.* Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? *Mol Chem Neuropathol* 1995;**26**:231–45.
- 23 Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. *NeuroRx* 2004;**1**:213–25.
- 24 Mehnert MJ, Agesen T, Malanga GA. "Heading" and neck injuries in soccer: a review of biomechanics and potential long-term effects. *Pain Physician* 2005;**8**:391–7.
- 25 Hu YY, He SS, Wang X, *et al.* Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. *Am J Pathol* 2002;**160**:1269–78.
- 26 Hu YY, He SS, Wang XC, *et al.* Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. *Neurosci Lett* 2002;**320**:156–60.
- 27 Norgren N, Sundstrom P, Svenningsson A, *et al.* Neurofilament and glial fibrillary acidic protein in multiple sclerosis. *Neurology* 2004;**63**:1586–90.
- 28 Frenguelli A, Ruscito P, Biccio G, *et al.* Head and neck trauma in sporting activities. Review of 208 cases. *J Craniomaxillofac Surg* 1991;**19**:178–81.

BMJ Clinical Evidence—Call for contributors

BMJ Clinical Evidence is a continuously updated evidence-based journal available worldwide on the internet which publishes commissioned systematic reviews. *BMJ Clinical Evidence* needs to recruit new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine, with the ability to write in a concise and structured way and relevant clinical expertise.

Areas for which we are currently seeking contributors:

- Secondary prevention of ischaemic cardiac events
 - Acute myocardial infarction
 - MRSA (treatment)
 - Bacterial conjunctivitis
- However, we are always looking for contributors, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) valid studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we will publish.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with *BMJ Clinical Evidence* editors to ensure that the final text meets quality and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The *BMJ Clinical Evidence* in-house team will conduct the searches for contributors; your task is to filter out high quality studies and incorporate them into the existing text.
- To expand the review to include a new question about once every 12 months.

In return, contributors will see their work published in a highly-rewarded peer-reviewed international medical journal. They also receive a small honorarium for their efforts.

If you would like to become a contributor for *BMJ Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to CECommissioning@bmjgroup.com.

Call for peer reviewers

BMJ Clinical Evidence also needs to recruit new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity and accessibility of specific reviews within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Reviews are usually 1500–3000 words in length and we would ask you to review between 2–5 systematic reviews per year. The peer review process takes place throughout the year, and our turnaround time for each review is 10–14 days. In return peer reviewers receive free access to *BMJ Clinical Evidence* for 3 months for each review.

If you are interested in becoming a peer reviewer for *BMJ Clinical Evidence*, please complete the peer review questionnaire at www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp